**Francisco Capani**

Biomedical Research Center, Interamerican Open University (CAECIHS-UAI), National Research Council (CONICET), Buenos Aires, Argentina

Instituto Universitario de Ciencias de la Salud, Fundación H.A Barceló, Buenos Aires, Argentina

> Department of Biology, John F. Kennedy University, Buenos Aires, Argentina

> > **1**

Section 1

Neuroprotection

in Alzheimer's and

Parkinson's Diseases

Facultad de Medicina, Universidad Autónoma de Chile, Santiago, Chile Section 1

Neuroprotection in Alzheimer's and Parkinson's Diseases

**3**

and pain.

**Chapter 1**

**Abstract**

and Facts

*and Rodolfo A. Kölliker Frers*

models of neurodegeneration.

**1. Introduction**

Neuroprotective Properties of

Cannabinoids in Cellular and

Animal Models: Hypotheses

*Lucas D. Udovin, Andrea Aguilar, Tamara Kobiec,* 

**Keywords:** Parkinson's disease, Alzheimer's disease, endocannabinoids,

The palmitoylethanolamide (PEA) is an endogenous biologically active lipids belonging to the family of the endogenous cannabinoid. PEA has many uses in a range of therapeutics areas, such as: neurological diseases, neurodegeneration,

Several studies have been carried out to define the molecular mechanism of PEA. However, at time, it was proposed that the existence of a mechanism

palmitoylethanolamide (PEA), dopaminergic neurons

*María I. Herrera, Santiago Perez Lloret, Nicolás Toro Urrego* 

Progressive neuronal loss is a typical characteristic of neurodegenerative diseases. In Parkinson's disease, the loss of dopaminergic neurons in the basal ganglia results in impaired mobility and flawed muscle control. The loss of cholinergic neurons largely in the basal forebrain contributes to memory and attention deficits and the overall cognitive impairment in Alzheimer's disease. This being said, neuroprotective drugs should be expected to preserve and/or restore the functions affected by neuronal loss, and substantially prevent cell death. The endocannabinoid system, comprising lipid mediators able to bind to and activate cannabinoid receptors, has emerged as a therapeutic target of potential interest in a variety of central nervous system diseases. Palmitoylethanolamide (PEA) is one of the most important endocannabinoids, which has a key role in modulating oxidative stress and inflammatory response with neuroprotective potential in neurological disorders. Neurodegenerative diseases undergo varied, progressive stages. The current therapeutical approaches are beginning to fall short when it comes to meet the expected results, urging to either develop or identify or develop new effective treatments. This chapter discusses the neuroprotective potential of new drugs, aiming to shed some light on their proposed mechanism of action and their effect in cellular and animal
